Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma

Modern Pathology

Volumn 29, Issue 11, 2016, Pages 1433-1442

  Lee, Lik Hang ^a   Cavalcanti, Marcela S ^a   Segal, Neil H ^a   Hechtman, Jaclyn F ^a   Weiser, Martin R ^a   Smith, J Joshua ^a   Garcia Aguilar, Julio ^a   Sadot, Eran ^a   Ntiamoah, Peter ^a   Markowitz, Arnold J ^a   Shike, Moshe ^a   Stadler, Zsofia K ^a   Vakiani, Efsevia ^a   Klimstra, David S ^a   Shia, Jinru ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; ADOLESCENT; BIOSYNTHESIS; COLORECTAL TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84979306738     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.139     Document Type: Article

References (28)

1. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-144.
2. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515: 563-567.
3. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PDL1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-562.
4. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
5. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366: 2455-2465.
6. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-1030.
7. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015;23:32-38.
8. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-5074.
9. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-3175.
10. Le DT, Uram JN, Wang H et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-2520.
11. Mantovani A, Romero P, Palucka AK et al. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008;371:771-783.
12. Shia J, Ellis NA, Paty PB et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003;27:1407-1417.
13. Goldstein J, Tran B, Ensor J et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)Ann Oncol 2014;25:1032-1038.
14. Nordholm-Carstensen A, Krarup P-M, Morton D et al. Danish Colorectal Cancer Group. Mismatch repair status and synchronous metastases in colorectal cancer: a nationwide cohort study. Int J Cancer 2015;137: 2139-2148.
15. Perkins NJ, Schisterman EF. The inconsistency of "Optimal" cut-points using two ROC based criteria. Am J Epidemiol 2006;163:670-675.
16. Madore J, Vilain RE, Menzies AM et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28:245-253.
17. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028.
18. Passiglia F, Bronte G, Bazan V et al. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget 2016; e-pub ahead of print.
19. Shia J, Kuk D, Schultz N et al. Comprehensive morphological assessment of colorectal cancers characterized by The Cancer Genome Atlas (TCGA) identifies specific morphology-molecular alteration associations [abstract]. Mod Pathol 2016;29(Suppl 2):200A.
20. Lal N, Beggs AD, Willcox BE et al. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology 2015;4:e976052.
21. Pagès F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666.
22. Klintrup K, Mäkinen JM, Kauppila S et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41:2645-2654.
23. Roxburgh CSD, Salmond JM, Horgan PG et al. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009;249:788-793.
24. Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008;14:1413-1417.
25. Ropponen KM, Eskelinen MJ, Lipponen PK et al. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;182:318-324.
26. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12: 252-264.
27. Llosa NJ, Cruise M, Tam A et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
28. Smyrk TC, Watson P, Kaul K et al. Tumor-infiltrating lymphocytes are a marker for microsatelliteinstability in colorectal carcinoma. Cancer 2001;91: 2417-2422.